Kathleen A. Neville, MD, MS, MBA, FAAP, FCCP, received an Executive MBA from the Bloch School of Management at the University of Missouri-Kansas City in 2016 and a Master of Science in Clinical Research from Indiana University, Bloomington in 2005. She also received an MD from the State University of New York Health Sciences Center at Brooklyn. In 2024, she served as Vice President, Head of Clinical Development, and Global Medical Lead for Vascular Malformations at RELAY THERAPEUTICS. She also served as Vice President and Head of Clinical Development at NIKANG THERAPEUTICS. From 2022 to 2024, she served as Vice President of Clinical Development at C4 THERAPEUTICS in Watertown, Massachusetts, overseeing the development of two assets in the clinical portfolio. From 2020 to 2022, she served as Senior Director of Immunology at Janssen Research & Development LLC. From 2018 to 2020, she served as Senior Director of Pediatric Drug Development in the Child Health Innovation Leadership Division in the Office of the Chief Medical Officer at Johnson & Johnson in Raritan, New Jersey. From 2015 to 2018, she was a Professor of Pediatrics at the University of Missouri-Kansas City and Children's Mercy Hospital. From 2005 to 2015, she was a Professor of Pediatrics at the Indiana University School of Medicine/Riley Hospital for Children (Indianapolis Children's Hospital). She is also a member of the American Academy of Pediatrics Committee and the FDA Pediatric Advisory Committee.
Kathleen A. Neville, MD, MS, MBA, FAAP, FCCP, received an Executive MBA from the Bloch School of Management at the University of Missouri-Kansas City in 2016 and a Master of Science in Clinical Research from Indiana University, Bloomington in 2005. She also received an MD from the State University of New York Health Sciences Center at Brooklyn. In 2024, she served as Vice President, Head of Clinical Development, and Global Medical Lead for Vascular Malformations at RELAY THERAPEUTICS. She also served as Vice President and Head of Clinical Development at NIKANG THERAPEUTICS. From 2022 to 2024, she served as Vice President of Clinical Development at C4 THERAPEUTICS in Watertown, Massachusetts, overseeing the development of two assets in the clinical portfolio. From 2020 to 2022, she served as Senior Director of Immunology at Janssen Research & Development LLC. From 2018 to 2020, she served as Senior Director of Pediatric Drug Development in the Child Health Innovation Leadership Division in the Office of the Chief Medical Officer at Johnson & Johnson in Raritan, New Jersey. From 2015 to 2018, she was a Professor of Pediatrics at the University of Missouri-Kansas City and Children's Mercy Hospital. From 2005 to 2015, she was a Professor of Pediatrics at the Indiana University School of Medicine/Riley Hospital for Children (Indianapolis Children's Hospital). She is also a member of the American Academy of Pediatrics Committee and the FDA Pediatric Advisory Committee.